Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield AL provider‑administered pr…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - AlabamaPolicy N/A

    Provider-Administered Drug Precertification List / Precertification Requirements

    Customize your policy alerts

    Sign up for all blue cross blue shield - alabama policy alerts

    Know when blue cross blue shield - alabama releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists provider-administered drugs requiring precertification when given in office, outpatient facility, or home health; includes notes on gene therapy/cellular immunotherapy and special handling for PEEHIP members. Affects providers administering these drugs for Blue Cross Blue Shield - Alabama members.

    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyProvider-Administered Drug Precertification List / Precertification Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior authorization) before administering listed provider‑administered drugs in office, outpatient facility, or home health; gene therapy/cellular immunotherapy products require precertification for any setting.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    300+drugs listed requiring precertification (approx.)
    Gene Therapy/Cellular Immunotherapyproducts flagged for precertification regardless of setting

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Oncology onlyAvastin PA limitation
    Monthlylist update frequency

    Coverage Criteria & Scope Notes

    FOR PEEHIP Members Only: coverage excludes the provider-administered medications outlined in this drug policy from being accessed through a specialty pharmacy; these products must be obtained through buy and bill. There are three exceptions: Lemtrada will require the use of a specialty pharmacy, and Synagis and Spravato may be obtained either through buy and bill or through a specialty pharmacy. This PEEHIP-specific channel restriction applies only to the provider-administered drugs listed in this policy and does not change the requirement for precertification when drugs are administered in a provider's office, outpatient facility, or home health setting.

    Provider Responsibilities & Precertification Rules

    Prior Authorization

    Precertification required for listed provider‑administered drugs

    Prior authorization (precertification) is required for administration of the provider‑administered drugs listed in this policy when given in a provider's office, outpatient facility, or home health setting. Products indicated as Gene Therapy/Cellular Immunotherapy (+) require precertification for administration in any place of treatment.

    • Precertification applies to all drugs on the Provider‑Administered Drug Review Program list.
    • Gene Therapy/Cellular Immunotherapy products (marked with +) require precertification regardless of site of care.
    Note

    Channel restrictions and special handling for PEEHIP members

    For PEEHIP members, the listed provider‑administered medications must be obtained via buy‑and‑bill and are excluded from specialty pharmacy access, except where noted (Lemtrada requires specialty pharmacy; Synagis and Spravato may be obtained either by buy‑and‑bill or specialty pharmacy).

    • PEEHIP members: provider‑administered medications are excluded from specialty pharmacy and must be obtained through buy and bill.
    • Exceptions: Lemtrada requires specialty pharmacy; Synagis and Spravato may be provided via buy‑and‑bill or specialty pharmacy.
    Documentation Required

    Documentation required for precertification and submission guidance

    Submit precertification documentation as required for prior authorization of provider‑administered drugs; gene therapy/cellular immunotherapy products (marked +) must have precertification for administration in any setting. Use the payer's online policies and submission processes available at AlabamaBlue.com/Pharmacy for detailed submission guidance.

    • Precertification documentation is required for all listed provider‑administered drugs.
    • Gene therapy/cellular immunotherapy products require precertification regardless of place of treatment.
    • Refer to AlabamaBlue.com/Pharmacy (Provider‑Administered Drug Policies) for submission instructions and required documentation.
    Denial Risk

    Denial risk and billing impact for failure to precertify

    Failure to obtain precertification for listed provider‑administered drugs when administered in a provider's office, outpatient facility, or home health setting may result in denial of coverage. Gene therapy/cellular immunotherapy products will still require precertification even if administered outside those settings.

    • Denial risk: lack of precertification may lead to claim denial for services in office, outpatient facility, or home health.
    • Gene Therapy/Cellular Immunotherapy (+) remain subject to precertification requirements in all settings.

    Where Precertification Applies

    Step Therapy

    Precertification by site of care (office, infusion center, home)

    Precertification is required when these drugs are administered in a provider's office, outpatient facility, or during home health care. Gene Therapy/Cellular Immunotherapy products (marked +) require precertification for any place of treatment.

    • PEEHIP members: these drugs must be obtained via buy‑and‑bill (specialty pharmacy access is excluded) except for Lemtrada (requires specialty pharmacy) and Synagis and Spravato (may be obtained either way).
    • The product list is updated monthly; verify current requirements online at AlabamaBlue.com/Pharmacy.

    Key Definitions

    Provider-administered drugs — definition & attributes
    DefinitionMedications administered in a provider's office, outpatient facility, or home health setting that are subject to the payer's Provider-Administered Drug Review Program and require precertification when given in those settings.
    Place of administrationProvider's office, outpatient facility (infusion center), or home health setting — precertification is required for administrations in these locations.
    Requirement summaryPrecertification (prior authorization) is required for listed provider-administered drugs when administered in a provider's office, outpatient facility, or home health; failure to precertify may result in denial of coverage.
    PEEHIP channel restrictionFOR PEEHIP members: these provider-administered medications generally must be obtained via buy-and-bill, not through specialty pharmacy, with specific exceptions (Lemtrada, Synagis, Spravato).
    Gene Therapy/Cellular Immunotherapy (+) — definition & rule

    Policy Background & Purpose

    This document is an administrative precertification list, not clinical guidance. It identifies provider-administered drugs that are subject to the payer's Provider-Administered Drug Review Program and for which precertification is required when administered in a provider's office, outpatient facility, or home health setting. Treatments designated as Gene Therapy/Cellular Immunotherapy (+) require precertification regardless of place of treatment. The list is intended to communicate the scope of the review program and channel restrictions (for example, PEEHIP buy-and-bill requirements) so providers know when prior authorization and appropriate dispensing arrangements are necessary.

    Policy Summary
    PayerBlue Cross Blue Shield - Alabama
    PolicyProvider-Administered Drug Precertification List / Precertification Requirements
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain precertification (prior authorization) before administering listed provider‑administered drugs in office, outpatient facility, or home health; gene therapy/cellular immunotherapy products require precertification for any setting.
    SourceLink
    On This Page
    Coverage Criteria & Scope NotesProvider Responsibilities & Precertification RulesWhere Precertification AppliesKey DefinitionsPolicy Background & Purpose
    Definition of (+)A plus sign (+) indicates a Gene Therapy/Cellular Immunotherapy product.
    Precertification ruleGene Therapy/Cellular Immunotherapy products flagged with a (+) require precertification regardless of place of treatment (i.e., in any setting).
    List noticeProducts designated with + are included on the Provider-Administered Precertification Drug List and the list is updated monthly and subject to change without notice.